Thermo Fisher Scientific Inc. TMO has recently completed the acquisition of desktop scanning electron microscopy (SEM) solutions provider, Phenom-World. Financial terms of this transaction remain undisclosed.
The acquired company delivers advanced desktop SEMs plus imaging and analysis packages for research and industrial markets. The company aims to make imaging and analysis at the nanoscale available to every scientist in every lab. The company so far has put in efforts to develop high-quality electron microscope solutions that are functionally rich and simple to handle.
With the closing of Phenom-World purchase, based in Eindhoven, The Netherlands, Thermo Fisher plans to integrate the business into its Analytical Instruments segment. Per the company, addition of Phenom-World’s desktop SEM platform is likely to strengthen its position in electron microscopy and expand its entry-level and desktop SEMs offerings for customers working in materials science, industrial manufacturing, life sciences and electronics industries.
On another positive note, Thermo Fisher has undertaken several acquisitions of late to deploy capital effectively. Besides boosting revenue accretion, these strategic deals have historically benefited the company’s operating margin while also resulting in tax synergies.
The takeover of FEI has already started contributing to Thermo Fisher’s analytical instruments portfolio. Its last acquisition of Pantheon is also in line with its plans to expand biopharma services in Europe. The company’s other recent strategic purchases are Finesse Solutions and Alfa Aesar.
Over the past month, Thermo Fisher has been trading above the broader industry. The stock has gained 6.1%, higher than the broader industry’s gain of 2% over the same time frame.
Key Picks
Thermo Fisher carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Akari Therapeutics PLC. AKTX, Protagonist Therapeutics Inc. PTGX and XOMA Corp. XOMA, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Akari has a projected growth rate of 88.89% for the next quarter. The earnings surprises delivered by the company have been positive in the last three quarters with an average beat of 88.6%.
Protagonist has an expected earnings growth rate of 36.9% in 2017. The stock has soared an impressive 80.6% in the last six months.
XOMA is expected to score an impressive earnings growth rate of 99.2% in 2017. The stock has skyrocketed a whopping 406.4% in the last 6 months, despite a loss of 1.7% incurred by the broader industry.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment